Cargando…
Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1
INTRODUCTION: Hereditary Tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a defect in the tyrosine degradation pathway. Current treatment consists of 2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexanedione (NTBC) and a tyrosine and phenylalanine restricted diet. Recently, neuropsychol...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614617/ https://www.ncbi.nlm.nih.gov/pubmed/28949985 http://dx.doi.org/10.1371/journal.pone.0185342 |
_version_ | 1783266430534287360 |
---|---|
author | van Ginkel, Willem G. van Vliet, Danique Burgerhof, Johannes G. M. de Blaauw, Pim Rubio Gozalbo, M. Estela Heiner-Fokkema, M. Rebecca van Spronsen, Francjan J. |
author_facet | van Ginkel, Willem G. van Vliet, Danique Burgerhof, Johannes G. M. de Blaauw, Pim Rubio Gozalbo, M. Estela Heiner-Fokkema, M. Rebecca van Spronsen, Francjan J. |
author_sort | van Ginkel, Willem G. |
collection | PubMed |
description | INTRODUCTION: Hereditary Tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a defect in the tyrosine degradation pathway. Current treatment consists of 2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexanedione (NTBC) and a tyrosine and phenylalanine restricted diet. Recently, neuropsychological deficits have been seen in HT1 patients. These deficits are possibly associated with low blood phenylalanine concentrations and/or high blood tyrosine concentrations. Therefore, the aim of the present study was threefold. Firstly, we aimed to calculate how the plasma amino acid profile in HT1 patients may influence the presumptive brain influx of all large neutral amino acids (LNAA). Secondly, we aimed to investigate the effect of phenylalanine supplementation on presumptive brain phenylalanine and tyrosine influx. Thirdly, we aimed to theoretically determine minimal target plasma phenylalanine concentrations in HT1 patient to ensure adequate presumptive brain phenylalanine influx. METHODS: Data of plasma LNAA concentrations were obtained. In total, 239 samples of 9 HT1 children, treated with NTBC, diet, and partly with phenylalanine supplementation were collected together with 596 samples of independent control children. Presumptive brain influx of all LNAA was calculated, using Michaelis-Menten parameters (K(m)) and V(max)-values obtained from earlier articles. RESULTS: In HT1 patients, plasma concentrations and presumptive brain influx of tyrosine were higher. However, plasma and especially brain influx of phenylalanine were lower in HT1 patients. Phenylalanine supplementation did not only tend to increase plasma phenylalanine concentrations, but also presumptive brain phenylalanine influx, despite increased plasma tyrosine concentrations. However, to ensure sufficient brain phenylalanine influx in HT1 patients, minimal plasma phenylalanine concentrations may need to be higher than considered thus far. CONCLUSION: This study clearly suggests a role for disturbed brain LNAA biochemistry, which is not well reflected by plasma LNAA concentrations. This could play a role in the pathophysiology of the neuropsychological impairments in HT1 patients and may have therapeutic implications. |
format | Online Article Text |
id | pubmed-5614617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-56146172017-10-09 Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1 van Ginkel, Willem G. van Vliet, Danique Burgerhof, Johannes G. M. de Blaauw, Pim Rubio Gozalbo, M. Estela Heiner-Fokkema, M. Rebecca van Spronsen, Francjan J. PLoS One Research Article INTRODUCTION: Hereditary Tyrosinemia type 1 (HT1) is a rare metabolic disease caused by a defect in the tyrosine degradation pathway. Current treatment consists of 2-(2-nitro-4-trifluoromethylbenoyl)-1,3-cyclohexanedione (NTBC) and a tyrosine and phenylalanine restricted diet. Recently, neuropsychological deficits have been seen in HT1 patients. These deficits are possibly associated with low blood phenylalanine concentrations and/or high blood tyrosine concentrations. Therefore, the aim of the present study was threefold. Firstly, we aimed to calculate how the plasma amino acid profile in HT1 patients may influence the presumptive brain influx of all large neutral amino acids (LNAA). Secondly, we aimed to investigate the effect of phenylalanine supplementation on presumptive brain phenylalanine and tyrosine influx. Thirdly, we aimed to theoretically determine minimal target plasma phenylalanine concentrations in HT1 patient to ensure adequate presumptive brain phenylalanine influx. METHODS: Data of plasma LNAA concentrations were obtained. In total, 239 samples of 9 HT1 children, treated with NTBC, diet, and partly with phenylalanine supplementation were collected together with 596 samples of independent control children. Presumptive brain influx of all LNAA was calculated, using Michaelis-Menten parameters (K(m)) and V(max)-values obtained from earlier articles. RESULTS: In HT1 patients, plasma concentrations and presumptive brain influx of tyrosine were higher. However, plasma and especially brain influx of phenylalanine were lower in HT1 patients. Phenylalanine supplementation did not only tend to increase plasma phenylalanine concentrations, but also presumptive brain phenylalanine influx, despite increased plasma tyrosine concentrations. However, to ensure sufficient brain phenylalanine influx in HT1 patients, minimal plasma phenylalanine concentrations may need to be higher than considered thus far. CONCLUSION: This study clearly suggests a role for disturbed brain LNAA biochemistry, which is not well reflected by plasma LNAA concentrations. This could play a role in the pathophysiology of the neuropsychological impairments in HT1 patients and may have therapeutic implications. Public Library of Science 2017-09-26 /pmc/articles/PMC5614617/ /pubmed/28949985 http://dx.doi.org/10.1371/journal.pone.0185342 Text en © 2017 van Ginkel et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article van Ginkel, Willem G. van Vliet, Danique Burgerhof, Johannes G. M. de Blaauw, Pim Rubio Gozalbo, M. Estela Heiner-Fokkema, M. Rebecca van Spronsen, Francjan J. Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1 |
title | Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1 |
title_full | Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1 |
title_fullStr | Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1 |
title_full_unstemmed | Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1 |
title_short | Presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with Tyrosinemia type 1 |
title_sort | presumptive brain influx of large neutral amino acids and the effect of phenylalanine supplementation in patients with tyrosinemia type 1 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614617/ https://www.ncbi.nlm.nih.gov/pubmed/28949985 http://dx.doi.org/10.1371/journal.pone.0185342 |
work_keys_str_mv | AT vanginkelwillemg presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1 AT vanvlietdanique presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1 AT burgerhofjohannesgm presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1 AT deblaauwpim presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1 AT rubiogozalbomestela presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1 AT heinerfokkemamrebecca presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1 AT vanspronsenfrancjanj presumptivebraininfluxoflargeneutralaminoacidsandtheeffectofphenylalaninesupplementationinpatientswithtyrosinemiatype1 |